Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

BeneChill raises $13.5m in series C

This article was originally published in Clinica

  • News

BeneChill, a developer of rapid, non-invasive cooling devices for treating hypothermia, has completed a $13.5m series C financing.

The round was led by new investor HealthCap, of Stockholm, Sweden. Previous investors in San Diego, California-based BeneChill also participated in the fundraising.

The CE-marked RhinoChill
Illustration: BeneChill

The proceeds will be used to fund early commercialisation of the company's CE-marked RhinoChill intra-nasal cooling device.

Early last week, InnerCool Therapies, a fellow San Diego firm that also specialised in hypothermia treatments, was bought by Philips Healthcare for an overall value of $12.75m.

Table

View full table

Topics

Tags:
Medical Device
Latest Headlines

Xaira Launches With $1bn-Plus And End-To-End AI Strategy

Biogen Sees Improving Momentum In Slow Leqembi Launch

Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative

Day One Springs Into Commercial Action With Ojemda Approval

See All
UsernamePublicRestriction

Register

MT043872

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By